肿瘤预防与治疗2017，Vol.30Issue(4)：265-270,6.DOI:10.3969/j.issn.1674-0904.2017.04.005
同步放化疗联合恩度治疗ⅢB和Ⅳ期非小细胞肺癌临床研究
Study on Concomitant Radiotherapy and Chemotherapy Combinating with Endostatin for ⅢB and Ⅳ Stage Non-small Cell Lung Cancer
摘要
Abstract
Objective:To evaluate the efficacy and toxicity of concomitant radiotherapy and chemotherapy combinating with endostatin for ⅢB and Ⅳ stage non-small cell lung cancer (NSCLC).Methods:60 cases of ⅢB and Ⅳ stage NSCLC were enrolled and randomized into two groups.Group A:30 cases with ⅢB and Ⅳ stage NSCLC were treated with 4 cycles of paclitaxel (135mg/m2,d1),cisplatin (25mg/m2/d,d1 ～ d3) and endostatin (15mg/d,d1 ～ d14).By concomitant radiotherapy(IGRT),the dose of central tumor and lymph node are the same:65-70Gy,peripheral tumor is 66-90Gy.Group B:30 cases were treated with the same way besides endostatin.Results:All patients finished treatment.Acute radiation-induced esophagitis was 13％ and 17％,pneumonitis was 3％ for the two groups,leucopenia was 67％ and 83 ％,the 1-year overall survival rate was 77％ and 67％,the 1-year local progression-free survival rate was 60％ and 50％ respectively in group A and B.Conclusion:Concomitant radiotherapy and chemotherapy combinating with endostatin for ⅢB and Ⅳ stage NSCLC can be well tolerated and the toxicity is tolerable.Results of this study are encouraging,though long-term results should be followed up.关键词
非小细胞肺癌/放化疗法/恩度/近期疗效Key words
Non-small cell lung cancer/Chemoradiotherapy/Endostatin/Prognosis分类
医药卫生引用本文复制引用
刘丽,李涛,郎锦义,张军,李柏森,徐柯..同步放化疗联合恩度治疗ⅢB和Ⅳ期非小细胞肺癌临床研究[J].肿瘤预防与治疗,2017,30(4):265-270,6.基金项目
四川省科技厅科研项目(编号 05SG022-013) （编号 05SG022-013）
